Neurelis announces commercial availability of Valtoco® (Diazepam nasal spray) for seizure cluster rescue
Chuck DeWildt, Chief Commercial Officer at Neurelis, announced Maxor Specialty Pharmacy has been selected as the national pharmacy provider and has already begun filling patient prescriptions. “VALTOCO is the first commercial product for Neurelis and we are now rapidly building our commercial organization,” DeWildt said. “Working with Maxor allows us to expedite the availability of VALTOCO for patients, healthcare providers and care partners who need it in advance of VALTOCO availability in retail pharmacies in the near future.” He added that Maxor will be able to serve all patients regardless of the type of insurance (commercial, private insurance, Medicaid or Medicare).
